TRS-005

Primary objective To evaluate the safety and tolerability of single and multiple administrations of TRS005 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma, and to provide the recommended dose (RP2D) for Phase II clinical trials Secondary objectives (1) To evaluate the pharmacokinetic characteristics of single and multiple administrations of TRS005; (2) To preliminarily evaluate the clinical efficacy of TRS005 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma; (3) To evaluate the immunogenicity of TRS005 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.